Abstract:Background: The ataxia telangiectasia and Rad3-related (ATR) kinase plays a central role in the DNA damage response (DDR) by activating essential signaling pathways of DNA damage repair. Inhibiting normal ATR function leads to increasing accumulation of double-strand breaks (DSB), particularly in genomically unstable tumor cells with preexisting replication stress, resulting in further genomic instability, mitotic catastrophe, and cell death. Targeting ATR is, therefore, a relevant strategy for the development of novel anticancer agents. This study tested the antitumor effects induced by ATG-018, a novel small molecule ATR inhibitor, in preclinical tumor models. Methods: Firstly, the antiproliferative activity of ATG-018 was evaluated against a panel of 143 tumor cell lines. Cell proliferation was measured after 72 hours of exposure to ATG-018, using CellTiter-Glo Cell Viability Assay. An unbiased genomic analysis of the tested cell lines was used to discover potential predictive biomarkers. The activity of ATR-inhibition by ATG-018 was determined by measuring phospho-Ser345 CHK1 protein level in HT-29 cells, using pCHK1 AlphaScreen assay. A mobility shift-based ATR kinase reaction assay was used to assess the direct inhibition of ATR by ATG-018. The in vivo anti-tumor efficacy of ATG-018 was evaluated in LoVo (colorectal cancer), OE21 (esophageal cancer) and OCI-LY-19 (lymphoma) CDX mouse models, respectively. Results: Potent in vitro and in vivo anti-tumor efficacy has been observed for ATG-018. For cell proliferation inhibition, the IC50 of ATG-018 ranged from 0.22μM to 10μM in 137 out of 143 cell lines, including both solid tumor and hematological malignancies, while ATG-018 did not affect the viability of normal PBMCs. A series of genetic alterations has been discovered to be correlated with the sensitivity to ATG-018, which could be potential predictive biomarkers. For ATR activity inhibition, the IC50 of ATG-018 required for ATR downstream (CHK1) phosphorylation inhibition was 1.4nM in HT-29 cells and the IC50 required for inhibiting ATR kinase reaction was 16nM. Dose-dependent antitumor efficacy was observed with ATG-018 in LoVo, OE21 and OCI-LY-19 CDX models. 10 mg/kg ATG-018 showed a statistically significant antitumor activity in all the three CDX models. In the OCI-LY-19 CDX model, 10 mg/kg ATG-018 showed 73.52% TGI on day 14 after grouping (p value=0.0014), and 50mg/kg ATG-018 induced tumor regression. Conclusions: Single agent ATG-018 exhibited strong monotherapy efficacy in preclinical cancer models with certain homologous recombination deficiencies, suggesting a promising therapeutic strategy for such patient populations. Citation Format: Hui Yuwen, Ya Kong, Lulu Jiang, Min Deng, Jiamei Luo, Bin Jiang, Bing Hou, Bo Shan, Jay Mei. The novel ATR inhibitor ATG-018 is efficacious in preclinical cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2604.

Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells

Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase

AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

The effect of replication protein A inhibition and post-translational modification on ATR kinase signaling

Discovery of selective and potent ATR degrader for exploration its kinase‐independent functions in acute myeloid leukemia cells

Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment

Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells

The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs

Abstract 2604: the Novel ATR Inhibitor ATG-018 is Efficacious in Preclinical Cancer Models

Targeting ATR in patients with cancer

Discovery of Thieno[3,2-d]pyrimidine Derivatives As Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase.

ATR phosphorylates SMARCAL1 to prevent replication fork collapse

Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer

Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo

Inhibition of Wee1 Sensitizes AML Cells to ATR Inhibitor VE-822-induced DNA Damage and Apoptosis.

ATR inhibition radiosensitizes cells through augmented DNA Damage and G2 cell cycle arrest abrogation

Evidence of Improving Therapeutic Outcomes

ATR promotes clearance of damaged DNA and damaged cells by rupturing micronuclei

Mechanisms Responsible for the Synergistic Antileukemic Interactions Between ATR Inhibition and Cytarabine in Acute Myeloid Leukemia Cells

Synergistic Lethality Between Auranofin-Induced Oxidative DNA Damage and ATR Inhibition in Cancer Cells